ICON Public (NASDAQ:ICLR) Issues FY 2024 Earnings Guidance

ICON Public (NASDAQ:ICLR) issued an update on its FY 2024 earnings guidance on Saturday morning. The company provided earnings per share (EPS) guidance of 15.000-15.200 for the period, compared to the consensus estimate of 15.060. The company issued revenue guidance of $8.5 billion-$8.6 billion, compared to the consensus revenue estimate of $8.6 billion.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ICLR. The Goldman Sachs Group started coverage on shares of ICON Public in a research report on Thursday, June 6th. They set a buy rating and a $370.00 price target for the company. Robert W. Baird boosted their price target on ICON Public from $367.00 to $376.00 and gave the company an outperform rating in a report on Monday, July 8th. Truist Financial upped their price target on ICON Public from $367.00 to $383.00 and gave the company a buy rating in a research report on Friday. TD Cowen lifted their price objective on ICON Public from $349.00 to $373.00 and gave the stock a buy rating in a research report on Friday, May 31st. Finally, William Blair restated an outperform rating on shares of ICON Public in a report on Friday, May 31st. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus target price of $352.56.

ICON Public Trading Up 1.8 %

ICLR opened at $329.33 on Tuesday. The company has a quick ratio of 1.31, a current ratio of 1.31 and a debt-to-equity ratio of 0.36. ICON Public has a 52 week low of $221.20 and a 52 week high of $347.72. The stock has a market cap of $27.17 billion, a PE ratio of 40.06, a PEG ratio of 1.42 and a beta of 1.23. The business has a 50 day moving average of $322.38 and a 200-day moving average of $309.74.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $3.75 EPS for the quarter, beating the consensus estimate of $3.68 by $0.07. The business had revenue of $2.10 billion during the quarter, compared to analyst estimates of $2.14 billion. ICON Public had a return on equity of 12.06% and a net margin of 8.57%. The company’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.96 earnings per share. Equities research analysts predict that ICON Public will post 14.57 earnings per share for the current fiscal year.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.